Last updated: October 7, 2026
Bictegravir sodium is the integrase inhibitor component of Biktarvy, Gilead Sciences’ leading HIV treatment product. Lenacapavir sodium is Gilead’s long-acting capsid inhibitor, marketed as Sunlenca for heavily treatment-experienced adults with multidrug-resistant HIV. The two products have different commercial profiles: bictegravir generates multibillion-dollar annual revenue through a high-volume fixed-dose combination, while lenacapavir remains a specialty product with greater long-term upside if approved and adopted for HIV prevention.
Biktarvy generated approximately $11.85 billion in product sales in 2023, compared with approximately $10.39 billion in 2022. Sunlenca generated approximately $58 million in 2023, reflecting its restricted treatment population and initial commercial stage (Gilead Sciences, 2024a).
How does bictegravir sodium generate revenue?
Bictegravir sodium is not generally sold as a standalone product. Its commercial value is realized through Biktarvy, a once-daily fixed-dose tablet containing bictegravir, emtricitabine and tenofovir alafenamide.
| Product |
Active ingredients |
Company |
Primary use |
Commercial status |
| Biktarvy |
Bictegravir, emtricitabine, tenofovir alafenamide |
Gilead Sciences |
Complete HIV-1 treatment regimen |
Global commercial product |
| Sunlenca |
Lenacapavir |
Gilead Sciences |
Multidrug-resistant HIV-1 |
Commercial product in selected markets |
| Genvoya |
Elvitegravir, cobicistat, emtricitabine, tenofovir alafenamide |
Gilead Sciences |
HIV treatment |
Older integrase-based regimen |
| Triumeq |
Dolutegravir, abacavir, lamivudine |
ViiV Healthcare |
HIV treatment |
Competing integrase regimen |
| Dovato |
Dolutegravir, lamivudine |
ViiV Healthcare |
Two-drug HIV treatment |
Competing regimen |
Biktarvy’s revenue base rests on four factors:
- High treatment volume in the United States and other developed markets.
- Once-daily dosing with a single-tablet regimen.
- Strong efficacy and tolerability in treatment-naive and treatment-experienced patients.
- Broad use across commercial, Medicare and Medicaid channels.
Biktarvy has become a core component of Gilead’s HIV franchise and offsets declining sales from older products such as Atripla, Stribild and Genvoya.
What is the financial trajectory for Biktarvy and bictegravir?
Biktarvy’s sales trajectory remained strongly positive through 2023.
| Fiscal year |
Approximate Biktarvy sales |
Year-over-year trend |
| 2021 |
$8.62 billion |
Strong growth |
| 2022 |
$10.39 billion |
Approximately 21% growth |
| 2023 |
$11.85 billion |
Approximately 14% growth |
Sources: Gilead annual reports and Form 10-K filings (Gilead Sciences, 2022, 2023, 2024a).
Growth has been driven by continued switching from older regimens, new patient starts and product preference among prescribers. The product also benefits from the continuing shift toward tenofovir alafenamide-based regimens, which have a more favorable renal and bone profile than older tenofovir disoproxil fumarate products.
The growth rate is likely to moderate as the treated HIV population matures, competing integrase inhibitors remain available and U.S. pricing pressure increases. Biktarvy remains exposed to a later-stage loss-of-exclusivity event, but the timing depends on the enforceability of listed patents, pediatric extensions, settlement terms and any regulatory exclusivity attached to the product.
How does lenacapavir sodium generate revenue?
Lenacapavir sodium is commercialized as Sunlenca, an injectable HIV treatment administered in combination with other antiretroviral agents. It is intended for adults with multidrug-resistant HIV-1 whose current regimen is failing because of resistance, intolerance or safety concerns.
Sunlenca’s initial market is structurally smaller than Biktarvy’s market. It addresses a heavily treatment-experienced population rather than the entire newly diagnosed or virologically suppressed HIV population.
| Metric |
Biktarvy |
Sunlenca |
| Active pharmaceutical ingredient |
Bictegravir sodium in combination |
Lenacapavir sodium |
| Dosage form |
Once-daily oral tablet |
Long-acting injectable, with oral lead-in or loading regimen |
| Main population |
Broad HIV treatment market |
Multidrug-resistant HIV |
| Revenue scale |
Multibillion-dollar product |
Early commercial specialty product |
| Main value driver |
Patient volume and regimen switching |
Clinical need, duration of action and expanded indications |
| Key competitive threat |
Other integrase inhibitors and generic entry |
Long-acting regimens, new capsid inhibitors and prevention alternatives |
Gilead reported Sunlenca sales of approximately $58 million in 2023 (Gilead Sciences, 2024a). That figure was small relative to Biktarvy but does not reflect the potential market for expanded use in treatment or prevention.
What is the future market opportunity for lenacapavir?
Lenacapavir’s largest commercial opportunity is the possible expansion from salvage therapy into long-acting HIV prevention and broader treatment populations.
The drug’s six-month dosing schedule is commercially differentiated. If approved for pre-exposure prophylaxis, lenacapavir could compete with daily oral tenofovir-based prevention and other long-acting products. Its potential advantages include infrequent dosing and reduced dependence on daily adherence.
The commercial outcome would depend on:
- Regulatory approval in prevention.
- Delivery capacity for twice-yearly injections.
- Pricing relative to generic tenofovir/emtricitabine.
- Reimbursement by public and private payers.
- Provider infrastructure for administration.
- Patient acceptance of injectable prevention.
- Resistance management after missed or delayed injections.
- Global access programs and licensing arrangements.
A prevention indication could expand lenacapavir’s addressable population by orders of magnitude compared with Sunlenca’s current salvage-therapy market. It could also create a franchise with a different revenue profile from Biktarvy: lower treatment frequency, higher administration complexity and greater payer sensitivity.
What FDA regulatory status applies to bictegravir and lenacapavir?
Biktarvy was approved by the U.S. Food and Drug Administration in 2018 as a complete regimen for HIV-1 infection in adults. Its label was later expanded to include pediatric patients meeting specified weight and age requirements (FDA, 2018).
Sunlenca was approved by the FDA in December 2022 for adults with multidrug-resistant HIV-1 whose current antiretroviral regimen is failing because of resistance, intolerance or safety considerations. The FDA approval was based on the CAPELLA clinical program, which evaluated lenacapavir with an optimized background regimen (FDA, 2022).
| Product |
Initial U.S. FDA approval |
FDA pathway |
Approved role |
| Biktarvy |
2018 |
New drug application |
Complete HIV-1 treatment regimen |
| Sunlenca |
2022 |
New drug application |
Treatment of multidrug-resistant HIV-1 |
The regulatory distinction matters commercially. Biktarvy is prescribed broadly as a complete regimen. Sunlenca, in its initial indication, must be used with background therapy and is directed at a smaller population.
What patents protect bictegravir sodium and Biktarvy?
Biktarvy is protected by a combination of active-ingredient, formulation and combination-product patents listed in the FDA Orange Book. The relevant estate may include patents directed to:
- Bictegravir and related integrase inhibitor compounds.
- Bictegravir salts, including bictegravir sodium.
- Combinations of bictegravir with emtricitabine and tenofovir alafenamide.
- Pharmaceutical compositions and tablet formulations.
- Methods of treating HIV infection.
- Dosing and administration of the fixed-dose combination.
The commercial patent position should be assessed at the product level rather than by reviewing bictegravir sodium alone. Biktarvy’s protection is layered, and the practical generic-entry date may depend on which patents are challenged, which claims survive litigation and whether a generic applicant can launch a product that avoids enforceable claims.
Orange Book patent listings and expiration dates can change through corrections, patent-term adjustments, pediatric extensions and litigation outcomes. The FDA’s Orange Book remains the controlling public source for listed Biktarvy patents and associated exclusivity data (FDA, n.d.-a).
What patents protect lenacapavir sodium and Sunlenca?
Lenacapavir has a newer patent estate than bictegravir. Its protection is expected to include:
- Composition-of-matter patents covering lenacapavir.
- Salt and crystalline-form patents.
- Injectable formulation patents.
- Long-acting delivery technology.
- Methods of treating HIV.
- Methods of preventing HIV infection.
- Dosing schedules involving infrequent administration.
- Combination treatment with background antiretroviral therapy.
For lenacapavir, formulation and delivery patents may be commercially important because the drug’s value depends on long-acting administration. A competitor that cannot reproduce the same release profile may face development, manufacturing and clinical hurdles even after composition-of-matter protection becomes vulnerable.
Unlike small-molecule oral products, a generic or follow-on injectable would need to address manufacturing controls, impurity profiles, suspension properties, injection volume, stability and comparability. These factors can delay market entry beyond the nominal expiration of a basic active-ingredient patent.
When could generic competition affect Biktarvy?
Biktarvy’s generic-entry risk is material but not necessarily tied to a single date. Generic applicants can file Abbreviated New Drug Applications with Paragraph IV certifications against Orange Book patents before patent expiration.
A Paragraph IV filing would trigger a patent dispute if Gilead filed suit within the statutory period. Litigation could result in:
- A 30-month FDA approval stay.
- A settlement with an agreed launch date.
- Invalidity or non-infringement findings.
- Partial entry against selected patents.
- A negotiated license for an authorized generic or third-party product.
The most likely initial generic challenge would target the fixed-dose combination or formulation patents rather than bictegravir sodium in isolation. Commercial launch could occur on the earliest of patent expiry, settlement permission or successful litigation outcome.
Which companies compete with bictegravir and lenacapavir?
Biktarvy competes primarily with other integrase inhibitor regimens.
Biktarvy competitors
- ViiV Healthcare’s Triumeq and Dovato, containing dolutegravir.
- Juluca, containing dolutegravir and rilpivirine.
- Gilead’s own Genvoya and Descovy-based regimens.
- Generic tenofovir/emtricitabine-based combinations.
- Long-acting cabotegravir and rilpivirine, marketed as Cabenuva by ViiV Healthcare and Janssen.
Lenacapavir’s direct commercial competition is more limited in salvage therapy. Its broader competitive set includes Cabenuva, oral integrase-based regimens, investigational capsid inhibitors and future long-acting prevention products.
What licensing deals affect lenacapavir?
Gilead has used licensing and partnership arrangements across its HIV portfolio, particularly for global access and distribution. Lenacapavir’s commercial value may also be affected by voluntary licensing for low- and middle-income countries if Gilead pursues broad prevention access.
Licensing can alter the market in three ways:
- It can accelerate geographic availability without requiring Gilead to build every local commercial channel.
- It can create lower-priced competition in selected countries.
- It can reduce the revenue captured per patient while increasing total treated or protected patients.
The financial effect depends on territory, indication, royalty rates, manufacturing responsibility and whether licensed products are limited to public-sector procurement.
What manufacturing and intellectual-property barriers affect generic entry?
Bictegravir tablets are comparatively easier to reproduce than lenacapavir injections, but the combination product still requires control of polymorphs, dissolution, content uniformity and stability.
Lenacapavir presents greater manufacturing complexity. Potential barriers include:
- Long-acting injectable formulation technology.
- Suspension homogeneity.
- Sterility and aseptic processing.
- Extended stability requirements.
- High-potency compound handling.
- Consistent release kinetics.
- Specialized clinical and regulatory comparability work.
These barriers may support longer commercial protection for Sunlenca than the basic patent term alone would suggest, although they do not prevent a well-capitalized injectable manufacturer from developing a competing product.
What revenue exposure does Gilead face?
Biktarvy is one of Gilead’s largest individual products. Its revenue exposure is therefore substantial. A rapid generic erosion event would affect Gilead’s HIV segment, cash flow and funding capacity for oncology, hepatitis and long-acting antiviral development.
Lenacapavir currently represents limited revenue exposure because Sunlenca sales are small relative to Biktarvy. Its strategic importance is greater than its current revenue contribution. A successful prevention indication could make lenacapavir a major growth asset and reduce Gilead’s dependence on the mature Biktarvy franchise.
| Risk or opportunity |
Biktarvy |
Lenacapavir |
| Current revenue contribution |
Very high |
Low |
| Near-term growth |
Moderate |
Potentially high |
| Generic risk |
Meaningful as patents mature |
Lower in early years |
| Formulation complexity |
Moderate |
High |
| Prevention opportunity |
Limited for current product |
Potentially substantial |
| Payer pressure |
High due to large budget impact |
Likely high if used broadly |
| Strategic role |
Current HIV revenue anchor |
Long-term growth platform |
How strong is the combined patent and commercial position?
Biktarvy has the stronger current commercial position because of its revenue scale, physician familiarity and broad label. Its main risk is eventual loss of exclusivity and slowing growth.
Lenacapavir has the stronger long-term optionality if its clinical and regulatory program expands into prevention. Its patent position is newer, while its formulation and administration requirements create additional barriers. Its principal risks are payer resistance, injection logistics, adherence after missed doses, resistance management and competition from other long-acting products.
Key Takeaways
- Bictegravir sodium is commercially monetized through Biktarvy, not as a standalone product.
- Biktarvy generated approximately $11.85 billion in 2023 sales, making it a core Gilead revenue asset.
- Lenacapavir sodium is marketed as Sunlenca for multidrug-resistant HIV and generated approximately $58 million in 2023.
- Biktarvy faces eventual Paragraph IV challenges and generic-entry risk as Orange Book patents mature.
- Lenacapavir has greater formulation and manufacturing complexity because it is a long-acting injectable.
- The largest upside for lenacapavir is expansion into HIV prevention and broader long-acting treatment.
- Gilead’s financial trajectory depends on extending Biktarvy’s commercial life while converting lenacapavir into a larger growth franchise.
FAQs
Is bictegravir sodium the same as Biktarvy?
No. Bictegravir sodium is one active ingredient in Biktarvy. Biktarvy also contains emtricitabine and tenofovir alafenamide.
Is lenacapavir sodium available as a generic?
No broadly marketed generic version of lenacapavir sodium was established in the cited regulatory and commercial sources. Sunlenca remains the reference product for its approved indication.
Does Sunlenca replace Biktarvy?
No. Sunlenca is approved for heavily treatment-experienced patients with multidrug-resistant HIV and is used with an optimized background regimen. Biktarvy is a complete once-daily treatment regimen for a much broader population.
Which product has greater commercial potential?
Biktarvy has the larger current revenue base. Lenacapavir has greater expansion potential if long-acting prevention and broader treatment indications receive regulatory approval and payer coverage.
What is the main investment risk for Gilead’s HIV franchise?
The primary risk is concentration in Biktarvy and the eventual erosion of its exclusivity. Lenacapavir’s ability to offset that risk depends on clinical expansion, regulatory execution, pricing and adoption of long-acting HIV prevention.
References
-
Food and Drug Administration. (2018). FDA approves new treatment for HIV infection. U.S. Department of Health and Human Services.
-
Food and Drug Administration. (2022). FDA approves new HIV drug Sunlenca. U.S. Department of Health and Human Services.
-
Food and Drug Administration. (n.d.-a). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.
-
Gilead Sciences, Inc. (2022). 2021 annual report and Form 10-K. Foster City, CA.
-
Gilead Sciences, Inc. (2023). 2022 annual report and Form 10-K. Foster City, CA.
-
Gilead Sciences, Inc. (2024a). 2023 annual report and Form 10-K. Foster City, CA.
